Background {#Sec1}
==========

Esophageal cancer is one of the most malignant solid tumors with a 5-year survival rate of \<19 % \[[@CR1]\]. Squamous cell carcinoma (SCC) is one of the two most common histologic types of esophageal cancer. The three main treatment options available for esophageal SCC (ESCC) are surgery, chemotherapy and radiotherapy. Studies evaluating the efficacy of combining these three modalities showed only a limited improvement in the prognosis \[[@CR2]--[@CR5]\].

A potential breakthrough may arise if the mechanism of ESCC proliferation can be clarified. Several studies reported that chemokines with lymphocyte chemoattractant capacities and chemokine receptors promote the progression of malignant tumors \[[@CR6]--[@CR10]\]. CXCR4, the receptor for chemokine CXCL12, was defined as the co-receptor used by the T-lymphotropic human immunodeficiency virus (HIV)-type 1 strains for cellular entry \[[@CR11]\]. AMD3100, a bicyclam in which two cyclam rings are tethered by an aromatic bridge, selectively blocks CXCR4 and inhibits HIV replication \[[@CR12]\]. Specifically, it blocks the interaction between gp120 (viral envelope glycoprotein) and CXCR4. The correlation was reported between the inhibitory effects of AMD3100 on HIV-1 replication, and CXCL12-mediated signal transduction (CXCL12-induced Ca^2+^ flux). AMD3100 is a highly specific CXCR4 antagonist inhibiting CXCL12-mediated Ca^2+^ flux in a number of cells expressing CXCR4, but has no inhibitory effect on chemokine induced signalling from other chemokine receptors \[[@CR11]\]. AMD3100 interacts with CXCR4 extracellularly and mechanistically prevents the binding of CXCL12 to CXCR4 and thus downstream signalling of CXCR4. \[[@CR11], [@CR13]\]. AMD3100 is not toxic to host cells at concentrations up to 500 mM and the CXCL12/CXCR4 blockade efficiently decreases cancer cell proliferation \[[@CR11], [@CR14]\].

Although the relationship between CXCL12/CXCR4 expression levels and cell behaviour was described in a variety of malignant tumors \[[@CR14]--[@CR18]\], few have assessed this relationship for esophageal cancer. In this study, we analysed the relationship between CXCL12/CXCR4 expression and tumor proliferation in patients with ESCC. We further investigated the correlation between CXCL12/CXCR4 expression levels and clinicopathological features. Our in vitro and in vivo results show that CXCL12 promotes ESCC proliferation.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Patients were enrolled in the study if they met the following inclusion criteria: (1) pathologically confirmed ESCC after radical esophagectomy at Keio University Hospital between 1997 and 2007; (2) no history of radiotherapy or chemotherapy prior to surgery; (3) R0 resection and (4) complete follow-up information. Each patient enrolled in this study signed an informed consent form.

This study was approved by the Institutional Review Board at Keio University School of Medicine.

Immunohistochemistry {#Sec4}
--------------------

Esophageal specimen tissues were obtained from surgical resection. Tumor samples were fixed with 10 % formalin in phosphate-buffered saline, embedded in paraffin and sectioned into 4-μm slices. The slides were deparaffinised in xylene and dehydrated in a graded ethanol series. The sections were incubated in Target Retrieval Solution PH6.0 (Dako, Glostrup, Denmark) for 10 min at 121 °C. The endogenous peroxidase activity was blocked by immersing the slides in 0.5 % periodic acid for 10 min at room temperature. After washing with water, the sections were treated with 4 % BlockAce (DS Pharma Biomedical, Osaka, Japan) for 30 min to block nonspecific reactions at 37 °C. The blocked sections were incubated with the primary diluted antibody at 4 °C overnight. The primary antibodies were diluted as follows: CXCL12 (MAB350, 1:200; R&D Systems, Minneapolis, USA) and CXCR4 (ab2074, 1:500; Abcam Inc., Cambridge, UK) were diluted in Can Get Signal Immunostain Solution A (Toyobo, Osaka, Japan), and Ki67 (SP6, 1:200; Thermo Fisher Scientific, Waltham, USA) was diluted in 4 % BlockAce. The sections were rinsed with Tris-buffered saline (TBS) followed by an incubation with ENVISION (Dako) for 30 min at room temperature. After the TBS washes, the sections were stained with a DAB kit (Dako), counterstained with hematoxylin and mounted. For each staining protocol, a negative control without the primary antibody was included. We evaluated CXCL12, CXCR4 and Ki67 expression on slides for viable ESCC cells belonging to the most invasive tumor lesion. We observed four different vision fields under high magnification (×400). To assess the immunoreactivity of CXCL12 and CXCR4, the sections were scored in terms of their proportion (score 0: −10 %, 1: 10--40 %, 2: 40--70 %, and 3: \>70 %) and intensity (score 0: none, 1: weak, and 2: strong). The immunoreactive score (IRS) was defined as the product of the proportion and intensity scores. For the final statistical analysis, an IRS value of 0 was ranked as the negative expression and IRS values of 1--6 were ranked as positive expression. The MIB-1 proliferation index was calculated as the percentage of Ki67 positive cells. Two investigators (UY and TH) blinded to the clinicopathological factors assessed the immunohistochemistry.

Animals {#Sec5}
-------

All animal experiments were executed according to Institutional Guidelines on Animal Experimentation at Keio University and were approved by The Keio University Institutional Animal Care and Use Committee. Female BALB/cA nude mice were purchased from Oriental Yeast Co., Ltd (Tokyo, Japan). The mice were maintained under specific pathogen-free conditions at Keio University Experimental Animal Center and fed sterile food and water. In each experiment, 10 mice aged 6 weeks were used. They were allocated to two groups and the weight prior to the intervention did not significantly differ among the groups (data not shown).

Esophageal cell lines {#Sec6}
---------------------

We used eight established ESCC cell lines (TE-1, 4, 5, 6, 8, 9, 10, and 11) provided by Dr. Nishihira (Tohoku University, Miyagi, Japan). The identity of each cell line was confirmed by short tandem repeat analysis \[[@CR10]\].

RNA extraction and quantitative real-time RT-PCR {#Sec7}
------------------------------------------------

Total RNA from each ESCC cell line was extracted and analysed by quantitative real-time RT-PCR using the 7300 Real Time PCR system (Applied BioSystems, Carlsbad, CA), TaqMan Gene Expression Master Mix (Applied BioSystems) and ready-to-use CXCR4/CXCL12 primers (Assay ID: Hs00607978_m1 for CXCR4 and Hs00171022_m1 for CXCL12; Applied BioSystems). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. We used human lymphocytes from a healthy donor (UY) as a positive control and distilled water without the template as a negative control. The relative quantity of CXCR4 and CXCL12 mRNA in ESCC cell lines was calculated using the ΔΔCt method. The expression levels of TE1 and TE4 were defined as 1 for the evaluation of CXCR4 and CXCL12 expression levels, respectively. All assays were performed in triplicate.

Establishment of a stable CXCL12-overexpressing cell line {#Sec8}
---------------------------------------------------------

CXCL12 mRNA was extracted from a healthy volunteer's (UY) lymphocytes. The full-length open reading frame was amplified and inserted into the plasmid vector pFLAG-CMV-4 (Sigma Aldrich, St. Louis, MO). The plasmids were transfected to TE4 cells using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA). When CXCL12 overexpression was confirmed by quantitative real-time RT-PCR, the stable transfectant was denoted TE4^CXCL12+^.

In vitro proliferation assay {#Sec9}
----------------------------

We examined the effect of CXCL12 on ESCC proliferation using water soluble tetrazolium (WST) salt. TE4 and TE4^CXCL12+^ (1 × 10^4^) were seeded in a 96-well plate (day 0) after overnight serum starvation. The following day, cells were exposed to different concentrations of CXCL12 (25 nM, R&D Systems) and/or AMD3100. Cell viability was measured using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) per the manufacturer's instruction after 72 h. The assays were performed in triplicate. We defined the 'proliferation index' as the absorbance ratio of day 3 over day 0.

In vivo proliferation assay {#Sec10}
---------------------------

Ten 6-week-old nude mice were injected with TE4^CXCL12+^ (1 × 10^6^) on day 0. Two dorsal skinfold chambers implanted on the back of each mouse. The following day, the animals were assigned to two different groups. The dorsal skinfold chamber was opened, and a mini-osmotic pump (Alzet, 200 μL, pumping rate: 1.0 μL/h) filled with AMD3100 (35 μg/μL) was implanted into five mice; a mini-osmotic pump filled with 0.1 % bovine serum albumin was implanted in five control mice. The pumps were exchanged under general anaesthesia every week. All operations were performed by the same surgeon. All animals underwent measurements of the tumor size on days 3, 7, 10 and 14 to assess whether the blockade of CXCL12-CXCR4 binding inhibits the tumor progression in vivo. One investigator (UY) who was blinded to the treatment measured the tumor size.

Statistical analyses {#Sec11}
--------------------

Mann-Whitney *U* test, Pearson's *χ*^2^ test or Fisher's exact probability test was used to assess the correlation between CXCL12/CXCR4 expression levels and clinicopathological characteristics. The Kaplan-Meier and log-rank tests were used for the survival analysis. Cox proportional hazard models were used for multivariate analysis of variables predicting postoperative survival. In the mouse model and in vitro proliferation assay, the Mann-Whitney *U* test was used to calculate the statistical significance of the tumor size or the absorbance, respectively. All statistical procedures were performed using SPSS v18.0 software (SPSS, Tokyo, Japan). A *p* value of less than 0.05 was considered to be statistically significant.

Results {#Sec12}
=======

CXCL12/CXCR4 expression and clinicopathological characteristics {#Sec13}
---------------------------------------------------------------

The patient characteristics are presented in Table [1](#Tab1){ref-type="table"}. The median age of the enrolled patients was 59 years (range: 44--79), and the male/female ratio was 71/8. Representative images of immunohistochemistry are shown in Fig. [1](#Fig1){ref-type="fig"}. Forty-eight patients (61 %) were positive for CXCR4 and 62 (78 %) for CXCL12 expression (Table [2](#Tab2){ref-type="table"}). The group with a positive CXCL12 expression was more likely to also have a positive CXCR4 expression compared with the group with negative CXCL12 expression; 41 patients (52 %) were positive for both CXCR4 and CXCL12. We found that patients with a positive expression of CXCL12 tended to have a higher lymph node recurrence rate than other patients (Table [3](#Tab3){ref-type="table"}, *p* = 0.08). No other significant correlation between the expression of CXCR4 or CXCL12 and other clinicopathological factors was found.Table 1Patient characteristicsPatients (*n* = 79)Age (median, range)59 (44--79)Gender (male/female)71/8Histological grade (1/2/3)16/57/6Depth of tumor invasion (Tis/T1/T2/T3)10/35/7/27Lymph node metastases (+)46 (58 %)Lymphatic invasion (+)58 (73 %)Vessel invasion (+)35 (44 %)Adjuvant therapy (none/chemotherapy/chemoradiotherapy)62/16/1Initial recurrence after surgery (none/lymph node/distant organ/both lymph node and distant organ)45/14/10/10Fig. 1Representative images of immunohistochemical staining of CXCL12 and CXCR4Table 2Relationship between CXCR4 and CXCL12 expressionCXCR4 (−)CXCR4 (+)TotalCXCL12 (−)10 (13 %)7 (9 %)17 (22 %)CXCL12 (+)21 (27 %)41 (52 %)62 (78 %)Total31 (39 %)48 (61 %)79*p* = 0.09Table 3Relationship between expression of CXCL12/CXCR4 and clinicopathological factorsAll patients (*n* = 79) (%)CXCR4(+)CXCR4(−)*p*CXCL12(+)CXCL12(−)*pn* = 48 (61)*n* = 31 (39)*n* = 62 (78)*n* = 17 (22)Age, median (range)58.5 (44--79)61 (44--74)0.84^c^59 (44--79)57 (50--70)0.84^c^Gender Male44270.71^a^54170.19^a^ Female4480Histological grade 11150.69^b^1240.90^b^ 234234512 33351Pathological T Tis550.63^b^820.39^b^ T12411287 T24370 T31512198Pathological N Positive28180.98^b^36100.96^b^ Negative2013267Lymphatic invasion Absent1380.90^b^1741.00^a^ Present35234513Vessel invasion Absent27170.90^b^3680.42^b^ Present2114269Recurrence of lymph node metastasis Positive13110.43^b^2220.08^a^ Negative35204015Recurrence of distant organ metastasis Positive1370.65^b^1730.54^a^ Negative35244514Recurrence of lymph node metastasis or distant organ metastasis means that the initial recurrence region after ESCC resection was lymph node or distant organ^a^Fisher's exact probability test^b^Pearson's χ-square test^c^Mann-Whitney *U* test

The mean follow-up time was 68 months. During follow-up, 34 (43 %) of 79 patients experienced tumor recurrence. Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} show the Kaplan--Meier curves of recurrence-free survival (RFS) and overall survival according to the expression of CXCL12 or CXCR4. The patients with a positive CXCL12 expression exhibited a significantly lower RFS (*p =* 0.02). CXCR4 expression, however, had no correlation with survival rate. Figure [4](#Fig4){ref-type="fig"} shows the comparison of the survival among the four groups (including CXCL12+ and CXCR4+, CXCL12+ and CXCR4-, CXCL12- and CXCR4-, and CXCL12- and CXCR4+), which showed no significant diffence among them. Patients with CXCL12-positive ESCC tended to have a poor prognosis regardless of the positive or negative expression of CXCR4.Fig. 2Survival curves of patients after esophagectomy with positive or negative CXCL12 expression. The patients with positive CXCL12 expression exhibit a significantly lower recurrence-free survival (*p* = 0.02)Fig. 3Survival curves of patients after esophagectomy with positive or negative CXCR4 expression. Positive expression of CXCR4 in ESCC is not correlated with survival rateFig. 4Survival curves of patients after esophagectomy among the four groups. No significant difference was observed; however, CXCL12-positive ESCC tended to be associated with a poor prognosis regardless of the positive or negative expression of CXCR4

Univariate and multivariate analyses were performed to determine the predictors of subsequent tumor recurrence. We evaluated six variables for survival prognosis by univariate analysis (Table [4](#Tab4){ref-type="table"}). We detected positive CXCL12 expression, lymph node metastasis, lymphatic invasion and vessel invasion as predictive markers of RFS. We performed the multivariate analysis for these four prognostic factors. In conclusion, a positive CXCL12 expression is an independent risk factor for subsequent tumor recurrence, showing the highest hazard ratio compared with other pathological features.Table 4Univariate and multivariate analyses to determine the risk factor for ESCC recurrenceRecurrence-free survivalUnivariateMultivariateCharacteristic*p* valueHR (95 % CI)*p* valuePositive CXCL12 expression (+/−)0.0215.12 (1.54--17.01)0.008Positive CXCR4 expression (+/−)0.97pT (≥pT3 vs \< pT3)0.10Lymph node metastasis (+/−)0.005Lymphatic invasion (+/−)0.0021.84 (1.24--2.72)0.002Vessel invasion (+/−)0.0042.13 (1.03--4.39)0.04*HR* hazard ratio, *CI* confidence interval

We demonstrated subgroup multivariate analysis by dividing the population into two groups by existence of adjuvant therapy. Positive CXCL12 expression was an independent risk factor for postoperative recurrence in the group without adjuvant therapy (*p* = 0.03, hazard ratio = 5.19, *n* = 62). However, no clinicopathological factors, including positive CXCL12 expression were detected as a significant risk factor for recurrence in the group with adjuvant therapy. This was likely due to an insufficient number of patients (*n* = 17).

The MIB-1 proliferation index was markedly higher in ESCC with a positive expression of CXCR4 or CXCL12, especially with positive CXCR4 expression (CXCR4 21.8 vs 7.6 %, *p* = 0.03; CXCL12 17.9 vs 7.6 %, *p* = 0.20; all percentage values are median). As shown in Table [5](#Tab5){ref-type="table"}, ESCC with positive expression of both CXCR4 and CXCL12 exhibited a significantly higher MIB-1 index than the other three groups (24.1 vs 7.5 %, *p* = 0.02). These results suggest that CXCL12 expression increases the proliferation of ESCC through signal transduction after binding to the CXCR4, which in turn leads to an earlier recurrence after surgery. We subsequently surveyed the relationship between CXCL12 expression and ESCC proliferation in vitro and in vivo.Table 5MIB-1index with or without CXCR4 or CXCL12 expressionCXCR4 negativeCXCR4 positiveCXCL12 negative9.6 % (0--58.1 %)7.2 % (0--52.5 %)*n* = 10*n* = 7CXCL12 positive7.2 % (0--51.1 %)24.1 % (0--68.2 %)*n* = 21*n* = 41All percentage values are median (range)*p* = 0.12

CXCR4 and CXCL12 mRNA expression in TE cell lines {#Sec14}
-------------------------------------------------

CXCR4 and CXCL12 mRNA expression in ESCC cell lines were assessed by quantitative real-time RT-PCR. All ESCC cell lines express CXCR4 at different levels (data not shown). Similarly, the CXCL12 mRNA expression level varies among cell lines, with the highest expression level seen in TE8 cells (Fig. [5a](#Fig5){ref-type="fig"}) and other cell lines showing a very low expression level or no expression at all. We selected the TE4 cell line for its low expression level of CXCL12 to establish transfectants overexpressing CXCL12. The original TE4 cell line was tumorigenic in nude mice. We established six different TE4^CXCL12+^ cell lines that overexpressed CXCL12 by gene transfer and used one for further investigation. This line was transplantable to mice and showed a 410-fold increase in CXCL12 expression compared with the untreated TE4 line (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5Quantitative real-time RT-PCR (evaluation of CXCL12 expression). **a** The CXCL12 mRNA expression level varies according to the cell lines. **b** The TE4^CXCL12+^ cell line overexpresses CXCL12 410-fold higher than the control TE4 cell line

In vitro proliferation assay {#Sec15}
----------------------------

Figure [6](#Fig6){ref-type="fig"} presents the proliferation index of TE4 in the WST cell proliferation assay with or without exposure to CXCL12 and in the presence or absence of AMD3100. When exposed to CXCL12, the TE4 cells showed a significantly higher proliferation index than control (*p* = 0.002). However, when exposed to AMD3100, the TE4 cells showed a significantly lower proliferation index than untreated TE4 cells (*p* = 0.001). CXCL12 was not able to increase the proliferation rate of TE4 cells exposed to AMD3100. Figure [7](#Fig7){ref-type="fig"} shows the proliferation index of TE4 and TE4^CXCL12+^ in the presence or absence of AMD3100. The TE4^CXCL12+^ cells showed a significantly higher proliferation index than the original TE4 cells (*p* = 0.03). Adding AMD3100 significantly decreased the proliferation of both TE4 and TE4^CXCL12+^ cells to the same extent (both *p* = 0.001). The decrease shown in Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"} was observed not only on day 3, but the tendency was already present on day 1 and 2 (data not shown).Fig. 6In vitro proliferation assay; TE4 with exposure to CXCL12 and/or AMD3100. TE4 cells exposed to CXCL12 exhibited a significantly higher proliferation index than untreated TE4 cells (*p* = 0.002), and TE4 cells exposed to AMD3100 showed a significantly lower proliferation index than untreated TE4 cells (*p* = 0.001). CXCL12 did not increase the proliferation rate of TE4 cells exposed to AMD3100Fig. 7In vitro proliferation assay; TE4 and TE4^CXCL12+^ cells exposed or not to AMD3100. TE4^CXCL12+^ cells showed a significantly higher proliferation index than wild type TE4 cells (*p* = 0.03). AMD3100 significantly decreases the proliferation of both TE4 and TE4^CXCL12+^ cells (both *p* = 0.001). Overexpression of CXCL12 did not increase the proliferation of TE4 exposed to AMD3100

These results indicate that CXCL12 expressed by TE4 or TE4^CXCL12+^ is secreted, binds to its specific receptor, CXCR4, on the cell membrane and stimulates cellular proliferation via signal transduction. AMD3100 inhibits the binding between CXCL12 and CXCR4 and subsequently decreases cell proliferation.

In vivo proliferation assay {#Sec16}
---------------------------

Figure [8](#Fig8){ref-type="fig"} shows the different tumor sizes following a subcutaneous injection of TE4^CXCL12+^ in the back of nude mice combined or not with a continuous subcutaneous infusion of AMD3100. Mice injected with TE4^CXCL12+^ and infused with AMD3100 had smaller tumors than the controls at all time points. On day 14, the tumor size was significantly decreased by the AMD3100 infusion (*p* = 0.03). This result indicates that AMD3100 decreases ESCC proliferation by inhibiting the CXCL12/CXCR4 signalling pathway artificially enhanced by TE4^CXCL12^. No adverse events were observed during the assay.Fig. 8In vivo proliferation assay; TE4^CXCL12+^ with or without infusion of AMD3100. TE4^CXCL12+^ mice continuously infused with AMD3100 showed smaller tumors than control mice at all time points. AMD3100 significantly decreases the tumor size on day 14 (*p* = 0.03)

Discussion {#Sec17}
==========

Our study on CXCL12, CXCR4 and the progression of ESCC has three significant findings. First, we demonstrate that a positive CXCL12 expression correlates significantly with a lower RFS rate in our patient population with ESCC. However, no significant correlation was detected between CXCL12 or CXCR4 expression levels and any clinicopathological factors, such as T/N stage, vessel or lymphatic invasion. These results suggest that CXCL12 expression in ESCC promotes the proliferation of the tumor and has a direct impact on the recurrence rate, independent of invasion or metastasis. The higher MIB-1 proliferation index with positive CXCL12 expression strongly supports this hypothesis. The multivariate analysis shows that positive CXCL12 expression is the only independent risk factor for postoperative recurrence with a hazard ratio of 5.12, superior to any of the other clinicopathological features. CXCL12 may be a very useful biomarker for predicting the outcome in ESCC patients, and more importantly, could be a critical diagnostic marker for selecting appropriate treatments. In contrast, CXCR4 expression was related to a higher MIB-1 index, but was not significantly correlated with RFS. This indicates that CXCL12 expression has a more prominent role in cellular proliferation, whereas CXCR4 expression only contributes.

Second, we report for the first time that the proliferative abilities of ESCC overexpressing or exposed to CXCL12 are significantly enhanced compared with wild-type cells in vitro. The fact that both CXCL12 overexpression and CXCL12 exposure similarly promote proliferation denotes that ESCC cells expressing CXCL12 secrete this factor. In addition, it also suggests that cellular proliferation is stimulated by the binding of CXCL12 to CXCR4 on the cell membrane. The selective CXCR4 blockade by AMD3100 inhibits proliferation regardless of CXCL12 overexpression or exposure.

Third, AMD3100 inhibits the tumor growth of ESCC expressing CXCL12 in vivo, which has not been previously reported. These results suggest the possibility for autocrine growth in ESCC similar to other carcinomas. Barbieri et al. reported that the overexpression of CXCL12 and CXCR4 induces autocrine and paracrine cellular proliferation in human pituitary adenomas \[[@CR14]\]. Moreover, Uchida et al. reported the involvement of an autocrine CXCL12/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma \[[@CR15]\]. It is possible that ESCC has an autocrine growth system; however, further studies are required to prove this.

Taken together, CXCL12 is not only a promising biomarker but also a molecular target for inhibiting proliferation. Using CXCL12 as a marker of poor prognosis, patients with CXCL12-positive ESCC are at a high risk of recurrence. Therefore, adjuvant or neo-adjuvant therapy might be indicated to avoid recurrence after an esophagectomy. In terms of molecular therapy, our study denotes the possibility of a cell proliferation blockade through the CXCL12/CXCR4 signalling axis. Our findings provide further evidence for the mechanism of CXCL12/CXCR4-mediated cellular proliferation, leading to novel therapeutic strategies to prevent tumor progression that may bring CXCL12/CXCR4-targeted therapy closer to clinical reality.

However, our immunohistochemical analyses demonstrated that patients with positive CXCL12 expression, including both CXCR4 positive and negative patients, have a poorer prognosis. This result indicates the possibility of additional mechanisms (other than binding to CXCR4 and an enhancement of proliferation) by which CXCL12 promotes ESCC development. Several studies have reported the relationship between CXCL12 and invasion of malignant tumors other than ESCC \[[@CR18]--[@CR22]\]. Kryczek et al. reported that CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers \[[@CR23]\]. Further studies are necessary to investigate the influence of CXCL12 on tumor cell mortality in the context of ESCC.

Several studies by other groups have demonstrated that the expression of CXCR4 or CXCL12 in cancer cells worsens the prognosis in patients with ESCC. Goto et al. showed that CXCR4 expression is associated with a poor prognosis in patients with ESCC \[[@CR24]\], while Sasaki et al. showed that CXCL12 and its receptor CXCR4 correlated with nodal metastasis in submucosal ESCC \[[@CR25]\]. Sasaki et al. further reported that positive CXCL12 expression was associated with poor prognosis in patients with ESCC; however, similar to our results, positive CXCR4 expression was not \[[@CR26]\]. We thought that this inconsistency was likely caused by the differences in the background of patients. Further assessment regarding CXCR4 expression in ESCC and its function is necessary.

AMD3100 did not fully prevent the proliferation of the TE4 and TE4^CXCL12+^ cell lines in our study, suggesting that CXCL12 may promote the proliferation of ESCC through other pathways in addition to CXCR4. For example, CXCR7, which is a novel receptor of CXCL12, was reported to be involved in the progression of several carcinomas \[[@CR27]--[@CR29]\]. However, we did not assess the expression of CXCR7 in ESCC, and we cannot discuss whether CXCL12-CXCR7 axis is related to the proliferation of the ESCC cell line. Furthermore, our IHC showed that CXCL12 positive expression was related to poor prognosis while CXCR4 positive expression was not. It is possible that this result was caused by CXCR7 involvement (i.e. CXCL12 promotes ESCC progression through not only CXCR4 but also CXCR7, and causes poorer RFS).

Although CXCL12 promoted the proliferation index in vitro, and AMD3100 suppressed the proliferation index in vitro, as well as the tumor size in vivo, our study did not disclose whether the CXCL12/CXCR4 axis is responsible for ESCC survival or apoptosis. Zhou et al. reported that CXCR4 mediates survival of glioma cells through Akt pathway \[[@CR30]\]. Moreover, Liao et al. reported that AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways \[[@CR31]\]. To assess whether CXCL12/CXCR4 is involved in survival or apoptosis of ESCC, further studies are needed, including an examination of signal transduction following CXCL12-CXCR4 binding.

This study has three other limitations. First, we only surveyed CXCL12 and CXCR4 expression of resected ESCC without preoperative therapy. We cannot conclude that CXCL12 expression is a biomarker of prognosis regardless of chemotherapy or radiation therapy prior to surgery. Second, we used one ESCC cell line, TE4, for in vitro and in vivo studies. TE4 and its transfectant demonstrated that CXCL12 increases cell proliferation; however, we did not test the other cell lines to exclude a cell line specific relationship. Third, we did not evaluate the downstream targets following CXCL12 stimulation. Several studies have reported the involvement of signal transduction, such as the ERK1/2 or Akt pathways in the proliferation of cancers \[[@CR6], [@CR14]\]. Therefore, further studies are required to assess the signal transduction after CXCL12-CXCR4 binding in ESCC.

Despite these limitations, our study demonstrates the potential for CXCL12 to become a useful marker for predicting the outcome in patients with ESCC and the development a new therapeutic target molecule to suppress ESCC progression.

Conclusions {#Sec18}
===========

In this study, we demonstrated that the expression of CXCL12 in ESCC is an independent risk factor of recurrence after surgery through immunohistochemistry and we showed that CXCL12 promotes ESCC proliferation. Blocking the binding of CXCL12 to CXCR4 decreases ESCC growth both in vitro and in vivo. Therefore, CXCL12 has the potential to become a biomarker for prognosis prediction and a therapeutic target in patients with ESCC.
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